Gilead Australia Fellowship Grants Program

A total of $300,000 AUD is available for the 2027 Fellowship Program.

Applicants may request up to $60,000 AUD per project and the requested level of funding should be stated at the time of application.

Amounts awarded may vary depending on project scope. Funding is entirely independent of the use of any therapeutic agent.

Applicants are required to demonstrate how their innovative, high-impact project meets the specified, measurable criteria to be awarded funding.

Funding is contingent upon:

• Granted ethics approval (if required)
• Project start in January 2027
• Project completion by July 2028

Funding is dependent on the project adhering to this timeframe and applicants must confirm their ability to meet this requirement at the time of application.

If granted, winners will be notified by Gilead and must return a signed grant agreement and bank details within two months of official notification.

Successful applicants are expected to communicate progress of their research during and post-completion of their project.

Applications are reviewed by an independent panel of Australian experts. Project applications are assessed on:

• Innovation – Novel approaches to improve patient outcomes and/or guide healthcare policy
• Relevance – Clear demonstration of local need and alignment with therapeutic areas of focus
• Feasibility – Specific steps, clear timelines, sufficient team capacity, good likelihood of ethics approval within timeframe
• Impact – Addresses important unmet needs, measurable objectives and outcomes, potential for scalability and long-term impact
• Budget – Transparent, justified, practical

Priority is given to proposals that:

• Fully meet all eligibility requirements, including completion by July 2028.
• Improve access to screening, support or treatment for underserved or minority patient groups.
• Are not currently receiving or due to receive funding from other sources.
• Have been or will be granted ethics approval, if required. Allocation of funding will be dependent on receipt of appropriate ethics approval. It is therefore essential that applicants can facilitate timely ethics approval so that the project can be completed in the assigned time frame. If for any reason ethics approval is not granted for a project, or if a project initially selected for funding is withdrawn from the Program before funding commences (e.g. due to securing funding from another source), where appropriate the judges reserve the right to select an alternative project to allocate funding to from a shortlist of the next highest-scoring projects.

All decisions by the independent judging panel to award or not award funding to a project, or to allow flexibility as detailed above, is final and no correspondence will be entered into regarding this. Funding decisions by the judging panel are entirely unrelated to the use of any particular therapeutic agent.

Applications open: Thursday 19th March 2026 (00:01 AEST)

Applications close: Thursday 14th May 2026 (23:59 AEST)

All applications must be submitted via the Gilead grants portal. Applicants must register an account before applying. Partially completed accounts/ applications can be saved and resumed. All applications must be completed and submitted by the closing date; incomplete applications and applications submitted after this will not be considered. Please note all correspondence and notifications to applicants will be via email where possible. Applicants should also monitor the grants portal for updates.

Application Requirements

For a full Grant applicant user guide, click here to download.

A complete application should include:

Project Description

• Objectives and an overview of the proposed project
• Target population and anticipated benefits
• Explanation of how the project is innovative
• Relevant current clinical or research activities
• Evidence supporting the project’s need

Implementation Plan

• Specific, measurable milestones and action steps
• Project timeline
• Team roles and responsibilities
• Data collection and analysis methodology
• Cost effectiveness and patient outcome measurement plans
• Details of ethics requirements and expected timelines

Budget and Governance

• A clear and detailed budget
• Disclosure of other funding applied for or received
• Contact details of the authorised organisational signatory

References

Include references where relevant and cite all statistics with appropriate sources.

Ethics Requirements

Obtaining ethics approval (if required) is a condition of funding being granted. Your application should indicate whether ethics approval is required and the estimated time of gaining this approval, confirming the body to which the application was made.

Note:

• Each section has a 200 word limit; information exceeding these limits will not be considered.
• Attachments will not be reviewed; all necessary information must be entered directly into the portal.
• No individual-level prescribing or treatment data should be provided.